NCT02265627View on ClinicalTrials.gov

Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 31, 2000

Primary Completion Date

September 30, 2000

Conditions
Hepatic Insufficiency
Interventions
DRUG

BIIL 284 BS

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY